Jim Cramer on Mannkind, Visa, FireEye and Linn Energy's Dividend

TheStreet's Jim Cramer is asked for advice on Mannkind, which has doubled in value after an FDA panel recommended approval of its insulin drug Afreeza, but has dropped off after the FDA delayed its decision. Cramer says Visa is getting "clubbed" and he needs to look into the credit card companies a little more, but FireEye is a "high-flyer." Finally, Cramer says he is unsure if Linn Energy's recently-declared dividend is safe. Send your Twitter questions to #CramerQ on Monday mornings.